Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bio-Rad Expands Portfolio of PrimePCR™ Assays for Droplet Digital™ PCR

Published: Wednesday, May 21, 2014
Last Updated: Wednesday, May 21, 2014
Bookmark and Share
Company expands its collection of validated assays for mutation detection and copy number variation.

Bio-Rad Laboratories, Inc. announces an expansion of its line of PrimePCR probe assays for Droplet Digital PCR that adds another 56 assays for mutation detection and 109 assays for copy number variation (CNV) analysis to Bio-Rad’s catalog of existing assays for use on its QX100™ and QX200™ Droplet Digital PCR systems.

biorad_primePCR.gifThe new Droplet Digital PCR (ddPCR™) assays are the only available assays that are predesigned and fully wet-lab validated for digital PCR, which frees researchers from time-consuming and labor-intensive assay design and experiment optimization.

Many conventional methods, such as qPCR and next-generation sequencing, offer poor selectivity, fail to detect events with frequencies of less than one in 100 wild-type sequences, and lack the resolution needed to accurately analyze CNV. However, Bio-Rad’s ddPCR technology provides an absolute measure of target DNA molecules and, together with PrimePCR mutation detection assays, can enable detection of one mutant molecule in a background of 2,000 wild-type molecules in a single well without the need for a standard curve. Measuring these extremely low levels of mutation abundance could lead to the development of new diagnostics that are less invasive and dramatically more sensitive. In addition, the high precision and absolute quantification made possible by PrimePCR ddPCR assays enable the quantitative discrimination
required to resolve small fold changes in gene copy numbers for CNV analysis.

Professor Per Guldberg, a group leader at the Danish Cancer Society, has been using PrimePCR ddPCR assays to detect mutations in neoplastic cells from body fluids. The assays are helping his lab uncover oncogenic biomarkers for bladder cancer, malignant melanoma, and other types of cancers.

“We have found the PrimePCR digital PCR assays to be very robust and specific with a high signal-to-noise ratio,” said Guldberg. “They have also helped us by entirely eliminating the need for cumbersome assay design and optimization.”

The mutation detection assays include those for deletions in the anaplastic lymphoma kinase (ALK) gene, which are believed to be associated with acquired resistance to ALK tyrosine kinase inhibitor (TKI) cancer therapy. The assays also target mutations associated with other cancers such as pancreatic cancer, melanoma, and lymphomas. Many of the CNV assay targets are associated with cancers (leukemia, melanoma, and uveal melanoma) and neurological diseases.

PrimePCR digital PCR assays are available in multiple reaction sizes and are compatible with both the QX100 and QX200 ddPCR systems using the ddPCR supermix for probes (no dUTP).

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Droplet Digital PCR Enables Measurement of Potential Cancer Survival Biomarker
Study paves the way for further research into the role of TIL quantification in immunotherapy and as a cancer survival predictor.
Tuesday, December 10, 2013
Bio-Rad Describes Detailed Neuroblastoma Study Using qPCR Analysis
The study uses examples from neuroblastoma research conducted at Bio-Rad and by researchers at Ghent University, Belgium.
Monday, August 04, 2008
Bio-Rad Launches new Website for Researchers Transfecting Mammalian Cells
Bio-Rad adds ‘Gene Transfer Protocols’ to its Gene Expression Gateway Web-site, dedicated to researchers working with mammalian cells.
Friday, June 27, 2008
A Comparative RNA Quantitation Analysis is Available
Bio-Rad Laboratories, Inc. has announced the availability of a technical paper that compares the performance of Bio-Rad’s Experion™ system to other methods of RNA quantitation.
Friday, March 14, 2008
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos